Evidence map›Paper›PMID 35072936›Full record

SynthesisJournal of nephrology2022

How good is a living donor? Systematic review and meta-analysis of the effect of donor demographics on post kidney transplant outcomes.

Maria Irene Bellini, Mikhail Nozdrin, Liset Pengel, Simon Knight, Vassilios Papalois

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Long-Term Outcomes Across Age and Risk Profiles in a Caucasian Living Kidney Donor Cohort.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Diversity, Equity, and Inclusion in Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  16. Article
  17. Survival Advantage Comparing Older Living Donor Versus Standard Criteria Donor Kidney Transplants.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Maria Irene BelliniDepartment of Surgical Sciences, Sapienza University of Rome, 00161, Rome, Italy. m.irene.bellini@gmail.com.ORCID 0000-0003-0730-4923
Mikhail NozdrinImperial College School of Medicine, London, SW7 2AZ, UK.
Liset PengelCentre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7HE, UK.
Simon KnightCentre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7HE, UK.
Vassilios PapaloisDepartment of Surgery and Cancer, Imperial College, London, SW7 2AZ, UK.
Imperial College London · GBNuffield Orthopaedic Centre · GBSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsLiving donor kidneys are considered the best quality organs. In the attempt to expand the donor pool, the donor's age, sex and body mass index (BMI) might be considered as potential determinants of the kidney transplant outcomes, and thus guide recipient selection. We aimed to investigate the effects of donor demographics on kidney function, graft and recipient survival, delayed graft function (DGF) and acute rejection (AR).

methodsSystematic review and meta-analysis. EMBASE, MEDLINE, Web of Science, BIOSIS, CABI, SciELO and Cochrane were searched using algorithms. NHBLI tools were used for risk of bias assessment. Mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) were calculated in Revman 5.4

resultsAltogether, 5129 studies were identified by the search algorithm; 47 studies met the inclusion criteria and were analyzed. No significant difference in recipient 1-year survival was found between recipients of donors aged < 50 vs donors aged > 50 (RR = 0.65 95% CI: 0.1-4.1), and recipients of donors aged < 60 vs donors aged > 60 (RR = 0.81 95% CI: 0.3-2.3). Graft survival was significantly higher in recipients of grafts from donors aged < 60. Risk of AR (RR = 0.62 95% CI: 0.5-0.8) and DGF (RR = 0.28 95% CI: 0.1-0.9) were significantly lower in recipients of grafts from donors aged < 60. One-year serum creatinine was significantly lower in recipients from donors aged < 60 years compared to donors aged > 60 years (MD = 0.3 mg/dl 95% CI: 0.1-0.9), although there was high heterogeneity. Recipients of grafts from male donors had lower 1-year serum creatinine (MD = 0.12 mg/dl 95% CI: 0.2-0.1) and higher eGFR compared to recipients of female donors (p < 0.00001). Donor obesity increased the incidence of delayed graft function but not acute rejection (RR = 0.66 95% CI: 0.32-1.34).

conclusionsOlder donor age was associated with worse post-transplant outcomes and recipients of male donors had better 1-year eGFR. Donor obesity affects the incidence of delayed graft function, but not the incidence of acute rejection in recipients.

Indexed as

Kidney TransplantationCreatinineDelayed Graft FunctionFemaleGraft RejectionGraft SurvivalHumansIncidenceLiving DonorsMaleObesityTissue DonorsCreatinineDonor’s demographicsGraft outcomesKidney transplantationLiving donation

Identifiers

PMID35072936
PMCPMC8995249
OpenAlexW4207079373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.